Zumutor Biologics Secures $7.3 Mn To Advance Clinical Trials For Cancer Therapy

Cancer treatment is changing fast. And somewhere in that shift, a biotech company operating out of both Bengaluru and Boston is doing work that genuinely deserves attention. Zumutor Biologics just closed a $7.3 million Series B round to push its cancer immunotherapy drug further into human trials. The cheque size is modest by global biotech standards. But when you look at who signed it and what the drug is actually doing inside the human body, the story gets a lot more interesting.

What Is Zumutor Biologics and What Does It Do?

Zumutor Biologics was founded in 2013 by Kavitha Iyer Rodrigues and Sohang Chatterjee. The company runs across two geographies. Boston for the headquarters, Bengaluru for the R&D. That split is not accidental. It is a cost-conscious, talent-rich model that more Indian deep tech founders should be paying attention to.

Zumutor is a leading immuno-oncology company in the space of targeted NK cell therapeutics. The company has two proprietary Antibody Engineering Platforms to develop novel immunotherapies that target innate immunity and regulate the tumor microenvironment.

So what does that actually mean? Here is the simple version. Your body has immune cells called Natural Killer cells. Their job is to find and destroy tumors. In many cancers, that system gets blocked. Zumutor’s entire bet is on reactivating it. The board includes Dr. Vijay Kuchroo, a leading immunologist and Professor of Neurology at Harvard Medical School, best known for discovering the TIM-3 checkpoint pathway. He has also co-founded CoStim, which was acquired by Novartis. That kind of scientific credibility is not easy to build. And it is not easy to attract either.

Zumutor Biologics Raises $7.3 Million in Series B Funding

Let’s be honest. $7.3 million is not a number that makes global biotech headlines on its own. But context matters.

Zumutor Biologics has raised $7.3 Mn, about ₹70 Cr, in its Series B funding round from existing investors Accel and Bharat Innovation Fund, alongside new investors Premji Invest, and angel investors like Ashish Kacholia and Raj Dandu.

Existing backers re-upping is one thing. New money coming in is another thing entirely. Premji Invest’s entry as a new backer is notable. The investment arm of Wipro founder Azim Premji’s family office adds a heavyweight name to a cap table that already includes Accel, signalling growing institutional confidence in India’s nascent immuno-oncology space.

So this is not just a funding round. It is a signal. When a name like Premji Invest shows up on a cap table for a clinical-stage biotech company, something has clearly checked out in their diligence.

Who Invested in Zumutor Biologics’ Latest Funding Round?

The investor mix here tells its own story.

Zumutor has 13 institutional investors including Accel, Bharat Innovation Fund and Siana Capital. Bharat Innovation Fund is the largest institutional investor in Zumutor. These are not first-time backers taking a blind bet. They have been in since early, watched the science mature, and kept writing cheques. That kind of conviction across multiple rounds is worth noting.

And then there are the angels. Ashish Kacholia and Raj Dandu participated as angel investors in the Series B round. Kacholia is one of India’s most well-known high-conviction investors. His presence alongside institutional names gives the round a different kind of texture.

Earlier backers across Zumutor’s funding history include Chiratae Ventures, Aarin Capital, and Karnataka Information Technology Venture Capital Fund (KITVEN). A long list. A patient list. And that patience is exactly what drug development demands.

What Is ZM008 and How Does It Fight Cancer?

Here is the kicker. Everything in this story comes back to one drug.

ZM008 is a novel fully human IgG1 monoclonal antibody against LLT1 (CLEC2D), which disrupts the interaction of LLT1-CD161 between NK cells and tumor cells. ZM008-mediated NK cell activation and subsequent T cell activation will modify the immune infiltrate in the tumor microenvironment driving eventual antitumor effects.

Put plainly: many tumors are “cold.” The immune system looks at them and basically does nothing. ZM008’s mechanism aims to convert cold tumors into hot tumors that might respond better to immunotherapy. That is a fundamentally different approach from a lot of what already exists in the market.

The Phase 1 trial is evaluating ZM008 across a wide range of advanced solid tumors including non-small cell lung cancer, esophageal cancer, head and neck squamous cell carcinoma, pancreas adenocarcinoma, biliary tract cancer, prostate cancer, urothelial carcinoma, colorectal cancer, and triple negative breast cancer.

That is a wide net. And a massive opportunity if the clinical data continues to hold up.

Preclinical studies support ZM008’s safety and efficacy across multiple tumor types, demonstrating increased NK and T cell activation, infiltration of the tumor microenvironment, enhanced IFN-gamma signaling, CD107a expression, and robust tumor cell cytotoxicity in vitro. The lab results are compelling. The real test is whether that translates to patients.

How Will Zumutor Use the $7.3 Million Funding?

The money is not sitting idle. There is a clear plan.

The startup plans to use the funds to complete its ongoing US FDA Phase 1 clinical study of ZM008, both as a monotherapy and in combination regimens. It will also use the capital to initiate Phase 1B expansion cohorts and global Phase 2 studies, including in India.

The combination being studied pairs ZM008 with pembrolizumab, one of the most widely used cancer immunotherapy drugs in the world right now. The preclinical work has shown remarkable activity both as a single agent and in combination with pembrolizumab.

The reality is that $7.3 million is lean for multi-geography clinical trials. But the capital is being deployed surgically. Zumutor’s Chief Scientific Officer Maloy Ghosh said: “Early clinical data from the ongoing Phase 1 study of ZM008 highlight the differentiated potential of novel NK checkpoint therapy for solid tumors. Building on these findings, we are expanding into dose expansion cohorts and combination studies across multiple tumor types.”

Specific milestones. Specific data targets. That is how you stretch a lean round in biotech without losing momentum.

How Much Has Zumutor Biologics Raised in Total?

A decade of work. That is what sits behind this Series B.

Zumutor has raised a total of $27.9 million across 8 funding rounds from 17 investors. The journey goes from a seed round in 2013 through multiple Series A tranches to this current close. Prior to this, Zumutor raised $6.2 Mn in its Series A4 funding round led by Siana Capital in 2021.

But here is what makes the timeline meaningful. In August 2023, the US FDA granted the company’s Investigational New Drug (IND) application for ZM008 to initiate a Phase 1, first-in-human, clinical study for the treatment of multiple solid cancers. And then, in June 2024, the first patient was dosed in its Phase 1 clinical trial with ZM008.

Ten years. One drug. One patient. That is how hard this space actually is. And that is also why the people who stay the course in biotech tend to build things that actually matter.

Why Are Investors Backing Cancer Immunotherapy Startups in India?

Zumutor Biologics’ $7.3 Mn raise does not sit in isolation. It is part of something bigger happening in Indian biotech right now.

The timing aligns with a broader Indian government push to grow the country’s biotech sector. Finance Minister Nirmala Sitharaman announced the “Biopharma SHAKTI” scheme with an outlay of ₹10,000 crore, and the government offers funding and incubation support to biotech startups through the BIRAC SEED programme.

And the market opportunity underneath all of this is real. India’s bioeconomy is projected to become a $300 billion market opportunity by 2030, drawing increased investor attention to the sector.

So the conditions are converging. Government support. Institutional capital. Clinical data starting to emerge from Indian-origin drug companies. The question now is execution. With Zumutor still classified as a breakout stage company despite being over a decade old, its progression into multi-geography Phase 2 trials will be a key test of whether Indian-origin biotechs can compete in clinical-stage drug development at a global level.

The next 18 months will answer that question. And Zumutor Biologics, with its NK cell checkpoint platform, an FDA-cleared IND, active Phase 1 data, and a freshly closed Series B, is in the best position it has ever been to make a real case.

What Is Zumutor Biologics

Zumutor Biologics Business Model